CY1120353T1 - Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας - Google Patents

Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας

Info

Publication number
CY1120353T1
CY1120353T1 CY20181100641T CY181100641T CY1120353T1 CY 1120353 T1 CY1120353 T1 CY 1120353T1 CY 20181100641 T CY20181100641 T CY 20181100641T CY 181100641 T CY181100641 T CY 181100641T CY 1120353 T1 CY1120353 T1 CY 1120353T1
Authority
CY
Cyprus
Prior art keywords
removal
connection cleaning
cleaning permanent
purchase
permanent purchase
Prior art date
Application number
CY20181100641T
Other languages
English (en)
Inventor
Samuel Ray TREJO
Robert Perry BRAKE
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120353(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of CY1120353T1 publication Critical patent/CY1120353T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση παρέχει τρόπο για την αφαίρεση μεγάλου κλάσματος ρύπων από πρωτεϊνικά παρασκευάσματα διατηρώντας παράλληλα υψηλό επίπεδο ανάκτησης χρησιμοποιώντας μέσο χρωματογραφίας πλοκαμοειδούς ανιονανταλλακτικής μήτρας. Χρησιμοποιώντας τις μεθόδους της εφεύρεσης, εκπλυμένοι ρύποι χρωματογραφίας συγγένειας μπορούν να αφαιρεθούν από παρασκευάσματα ανασυνδυασμένης πρωτεΐνης.
CY20181100641T 2013-03-14 2018-06-20 Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας CY1120353T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (1)

Publication Number Publication Date
CY1120353T1 true CY1120353T1 (el) 2019-07-10

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100641T CY1120353T1 (el) 2013-03-14 2018-06-20 Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας

Country Status (18)

Country Link
US (3) US20160024144A1 (el)
EP (3) EP3395423B1 (el)
JP (1) JP6457479B2 (el)
AU (1) AU2014240596B2 (el)
CA (1) CA2904411A1 (el)
CY (1) CY1120353T1 (el)
DK (2) DK2969099T4 (el)
ES (2) ES2964601T3 (el)
FI (1) FI3395423T3 (el)
HK (1) HK1220159A1 (el)
HU (2) HUE038565T2 (el)
LT (2) LT2969099T (el)
MX (2) MX365501B (el)
PL (2) PL2969099T5 (el)
PT (2) PT2969099T (el)
SI (2) SI2969099T2 (el)
TR (1) TR201809050T4 (el)
WO (1) WO2014159441A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
CN106536565A (zh) * 2014-06-13 2017-03-22 鲁宾有限公司 一种用于纯化TNFR‑Fc融合蛋白的方法
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
JP7065105B2 (ja) * 2017-02-09 2022-05-11 ブラッコ・スイス・ソシエテ・アノニム 可溶性ｐｓｇｌ－１タンパク質変異体の精製のための方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6149994A (en) 1996-06-21 2000-11-21 Merck Patent Gesellschaft Mit Beschrankter Haftung Polymerisable polyamide derivatives
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998058253A1 (de) 1997-06-18 1998-12-23 Merck Patent Gmbh Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CA2469815C (en) * 2001-12-21 2011-05-03 Immunex Corporation Methods for purifying protein
PL1869065T3 (pl) * 2005-03-11 2020-09-21 Wyeth Llc Sposób prowadzenia chromatografii podziałowej ze słabym wiązaniem
CA2668771C (en) * 2006-11-08 2016-03-15 Wyeth Rationally designed media for cell culture
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
JP5980782B2 (ja) * 2010-07-30 2016-08-31 ファイザー・インク タンパク質のタンデム精製
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
EP2729482B1 (en) * 2011-07-08 2018-03-07 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
JP6326371B2 (ja) * 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
SI2969099T2 (sl) 2013-03-14 2022-04-29 Amgen Inc. Odstranjevanje izluženega afinitetnega purifikacijskega liganda

Also Published As

Publication number Publication date
MX2015011994A (es) 2015-12-01
HK1220159A1 (zh) 2017-04-28
US20160024144A1 (en) 2016-01-28
EP3395423A1 (en) 2018-10-31
AU2014240596B2 (en) 2018-09-27
PL2969099T5 (pl) 2022-06-13
US11192919B2 (en) 2021-12-07
TR201809050T4 (tr) 2018-07-23
PT3395423T (pt) 2023-11-14
CA2904411A1 (en) 2014-10-02
US20190085021A1 (en) 2019-03-21
PT2969099T (pt) 2018-07-05
US11492372B2 (en) 2022-11-08
FI3395423T3 (fi) 2023-11-02
ES2964601T3 (es) 2024-04-08
WO2014159441A1 (en) 2014-10-02
EP3395423B1 (en) 2023-09-20
SI2969099T1 (sl) 2018-09-28
EP2969099B2 (en) 2021-12-22
JP2016513643A (ja) 2016-05-16
PL2969099T3 (pl) 2018-10-31
HUE038565T2 (hu) 2018-10-29
US20220144886A1 (en) 2022-05-12
ES2674697T5 (es) 2022-04-19
EP2969099B1 (en) 2018-04-25
JP6457479B2 (ja) 2019-01-23
DK2969099T4 (da) 2022-03-14
DK2969099T3 (en) 2018-07-09
LT2969099T (lt) 2018-09-10
SI3395423T1 (sl) 2023-12-29
EP4026596A1 (en) 2022-07-13
PL3395423T3 (pl) 2024-03-18
LT3395423T (lt) 2023-12-11
MX2019006568A (es) 2019-08-22
SI2969099T2 (sl) 2022-04-29
AU2014240596A1 (en) 2015-09-24
EP2969099A1 (en) 2016-01-20
ES2674697T3 (es) 2018-07-03
DK3395423T3 (da) 2023-11-20
HUE064450T2 (hu) 2024-03-28
MX365501B (es) 2019-06-05

Similar Documents

Publication Publication Date Title
CY1120353T1 (el) Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας
CO2017005639A2 (es) Anticuerpos anti-miostatina, polipéptidos que contienen regiones fc variantes
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
EA201990017A1 (ru) Антитела к миостатину и способы их применения
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MX2016009672A (es) Cartuchos utiles en limpieza de soluciones de dialisis.
BR112019012343A2 (pt) anticorpos il-11ra
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EP4324473A3 (en) Multiparametric nucleic acid optimization
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201992232A1 (ru) Композиции и способы для иммуноонкологии
HK1251584A1 (zh) 在親和層析中減少宿主細胞蛋白的方法
DE102015118537A8 (de) Abgaswärme-Rückgewinnungssystem
EP3278102A4 (en) Porous protein particles as carriers for actives
ECSP16076535A (es) Proteínas de fusión uti
DK3262168T3 (da) Værtscelleproteinmodifikation
DK2970378T3 (da) Hydrofob interaktionsproteinkromatografi under saltfrie betingelser
MX2017006373A (es) Medios de cromatografía y restauración de desempeño de resina de intercambio iónico.
MX2018003080A (es) Cartuchos utiles en soluciones de dialisis de limpieza.
HK1251583A1 (zh) 在親和層析中減少宿主細胞蛋白的方法